Healthcare Enterprise Group PLC
01 March 2005



Ebiox surface disinfectant, test results



Proven combatant ability against HIV and Avian Flu


Healthcare Enterprise Group PLC ("HCEG"), the international healthcare products
and Services Company announces that its TrionicTM product, from the Ebiox family
of products, has passed tests proving virucidal efficacy against the HIV and
Avian Flu ( Bird Flu) viruses. The tests, conducted by Microbiotest Inc of
Sterling, Virginia, USA conclude that using Trionic in a range of different
levels of dilution, applicable to the test, the two viruses became undetectable.


Reports this week surrounding the failure to reduce death rates from MRSA in the
UK and the need to remain vigilant with HIV, highlighted once again the need to
improve hygiene practices on our own doorstep. However, the problem of cross
contamination is much more widespread as evidenced by the growing fear
surrounding the spread of Avian Flu around the world.


According to the World Health Organisation, Avian Flu viruses can be readily
transmitted from farm to farm by mechanical means, such as contaminated
equipment, vehicles and cages. Stringent sanitary measures on farms can confer
some degree of protection, including hand hygiene and surface cleaning and
disinfection. HCEG recently completed agreement with Alpha Trading (Asia) Co Ltd
covering the distribution of Ebiox throughout Asia and reports encouraging
initial demand driven by the Avian Flu crisis.


TrionicTM  is a highly effective disinfectant already proven to combat MRSA,
SARS and other pathogens.  The product offers significant safety advantages over
all other commonly used disinfectants and does not contain alcohol, chlorine or
other irritating vapours. Moreover, TrionicTM  contains soil lifting agents and
biocides, which allow removal of microbes down to the molecular level, by
removing biofilms, which are believed to provide a rich breeding ground for the
development of resistant bacteria.  Many of the disinfectants currently used are
ineffective in dirty conditions, when soiling is present. TrionicTM works
differently, cleaning, disinfecting and deodorising in one to provide complete
decontamination.



Stuart Bruck, Chairman, Healthcare Enterprise Group PLC, commented:



"Avian Flu has been described as the number one health threat in the world and
huge resources are being channelled at controlling the disease which has a 76%
fatality rate.   As with HIV, MRSA, SARS and all other deadly diseases, the
microbes can harbour on surface areas, hence the need to regularly
decontaminate.  TrionicTM, through its unique properties, eradicates all surface
microbes and pathogens without the problem of resistant strains forming.



"We plan to market TrionicTM aggressively across all relevant industry sectors
internationally, thus affording rapid deployment to combat this serious
international problem."





1 March 2005




Enquiries:

Healthcare Enterprise Group                                      020 7351 7500
    Stuart Bruck                    Executive Chairman
    Gordon Wood                     Group Chief Operating Officer

College Hill                                                     020 7457 2020
    Nicholas Nelson
    Corinna Dorward




Note to editors



Ebiox



Ebiox produces a range of patented cleansing, decontamination and disinfectant
products.  The range includes hand hygiene products, environmental disinfectants
and products to clean and decontaminate surgical instruments.



The antibacterial handwash and handrub, are proven effective against MRSA,
E-coli and other important pathogens and are fully compliant with EU standards.
Uniquely, the products do not use alcohol, which has a drying effect and can be
a skin irritant.



The environmental disinfectant range including Trionic spray and wipes, lift and
remove dirt and bacteria, completely removing biofilms and cleaning to the
molecular level.  The product cleans through oxidation , not toxification which
means that there is no need to rotate disinfectants because there is no chance
of resistance developing (cf GMP guidelines).



Ebiox also offers a range of products for the effective cleaning of re-usable
instruments.  Critically, these products remove all debris prior to the
sterilisation process thereby ensuring complete decontamination.  They have
proven to be more effective than natural detergents and enzymatic detergents
currently available.



As well as the current range of products, Ebiox also has products for the
decontamination of dental  water lines and a veterinary product range, EbioxVET.



Healthcare Enterprise Group PLC



HCEG is quoted on the UK AIM stock market with its head office in London.   HCEG
is a business engaged in medical product distribution, occupational health,
first aid and medical consultancy markets.  These businesses underpin a range of
innovative medical devices, which will be introduced to the market via HCEG's
own distribution network on an international basis.







                      This information is provided by RNS
            The company news service from the London Stock Exchange
END

NRAPKDKQFBKKCNK